Genmab — Januar 2017
-
1 krone fra HOD.

-
AB reducerede netto med 10 K stk
-
Det lover godt for i morgen.
-
Altså det høje luk.
-
johnW. gå nu langt nok ned i kælderen. det her fortjener mere end en frikadellevin

-
nå men god aften alle og tak for i dag. nu vil jeg gå ned og få noget brunch (kl er jo ku n 11 her i NYC)
-
Millionær klubben gør status hver dag næsten lige op til kl 10 og i dag sidder de så og nævner de småting der sker I C20 ,, men har ikke en liste der omfatter hele C20 ,,, det er for uproffesionelt ,, Helge du har tilladelse til at give dem " en ordentlig næse" næste gang du er der ,,jeg er virkelig skuffet over deres løgnagtige udtalelser ,, det ser overhovedet ikke Genmab ,, selvom det var den der lå øverst i C20
-
Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. https://clinicaltrials.gov/ct2/show/NCT03011034?term=daratumumab&rank=15&submit_fld_opt=
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind